Compare AbCellera Biologics Inc (ABCL) vs Harmony Gold Mining Co. (HMY) Price & Performance

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

Harmony Gold (HMY) trades at $19.89, showing minimal daily change. The stock exhibits a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported robust 2024 results with $61.38B revenue and $8.59B net income, supported by a strategic pivot toward gold-copper production. Recent earnings have been mixed, with a Q4 2025 miss but prior beats.

The outlook is cautiously optimistic due to diversification benefits and solid cash flow, but risks include Fed rate sensitivity and execution challenges. Analyst sentiment is mixed with a majority Hold rating, reflecting balanced near-term prospects amid macroeconomic uncertainties.